At AlgoDx, the premise underlying all our research is the final product’s reliability. Our research methods are based on gold standards used in medical device and pharmaceutical development. We use a scientific, evidence-based approach with regulatory requirements in mind.
NAVOY® Product Suite
The NAVOY® portfolio includes machine learning algorithms specifically designed for Intensive Care. Developed for conditions with high unmet medical need, these algorithms are designed to generate robust clinical evidence for product claims, covering clinical and health-economic benefits as well as potential risks.
|
Pre-Clinical R&D
|
Regulatory Clearance
|
Clinical Validation
|
PMCF*
|
|
|---|---|---|---|---|
| NAVOY® Sepsis |
||||
| NAVOY® Acute Kidney Injury |
||||
| Undisclosed Therapeutic Indication | ||||
| Undisclosed Therapeutic Indication | ||||
| Undisclosed Therapeutic Indication | ||||
|
Ongoing
Complete * Post-Marketing Clinical Follow-up |
||||
Clinical Trials – AlgoDx sponsored clinical research
For more information on our ongoing clinical projects, visit clinicaltrials.gov
ExPRESS
Early Prediction of Sepsis in Hospitalized Patients Using a Machine Learning Algorithm, a Randomized Clinical Validation Trial.
Protocol number: NCT04570618
GENIUS
Integration and Evaluation of a Machine Learning Algorithm for Sepsis Prediction in an Electronic Health Record System – a Prospective Observational Study.
Protocol number: NCT05095220
AlgoDx Products in the Clinical Workflow